{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-216821","form_type":"8-K","ticker":"CBLL","cik":"0001861107","company_name":"Ceribell, Inc.","filed_at":"2026-05-11T20:16:47+00:00","discovered_at":"2026-05-11T20:18:00.308484+00:00","generated_at":"2026-05-11T20:19:48.347802+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Ceribell Q1 revenue $26.5M (+29% YoY); raises FY2026 guidance to $112-116M","bullets":["Revenue $26.5M, up 29% YoY; product $20.2M, subscription $6.3M, both +29%.","Net loss $19.7M ($0.52/sh) vs $12.8M ($0.36) YoY; adj. EBITDA loss $11.2M.","Launched neonate/pediatric EEG products; 680 active accounts at quarter end.","CMS proposed rule for NTAP reimbursement for delirium monitoring; final rule Aug 2026.","FY2026 revenue guidance raised to $112-116M (26-30% growth); cash $141.2M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-216821","json":"https://secwatch.observer/filing/0001193125-26-216821.json","markdown":"https://secwatch.observer/filing/0001193125-26-216821.md","text":"https://secwatch.observer/filing/0001193125-26-216821.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861107/000119312526216821/0001193125-26-216821-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861107/000119312526216821/cbll-20260511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T20:19:48.347802+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2cbd6548ede4e5f8f4fd8badcc0ef2ebc4b9ea1b","claim":"Ceribell, Inc. reported first quarter ended March 31, 2026 results: revenue $26.5 million, net income $19.7 million, EPS $0.52 net loss per share. Guidance raised.","evidence_excerpt":"serious neurological conditions, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 & Recent Highlights • Reported total revenue of $26.5 million in the first quarter of 2026, a 29% increase compared to the same period in 2025 • Ended the quarter with 680 total active accounts • Achieved gross margin of 87% • Initiated","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1861107/000119312526216821/0001193125-26-216821-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"$26.5 million"},{"label":"Net income","value":"$19.7 million"},{"label":"EPS","value":"$0.52 net loss per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}